Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd has informed BSE that its Board of Directors will meet on Wednesday, May 28, 2025, at the registered office of the company. The main agenda is to consider and approve the IND-AS compliant Standalone Audited Financial Results along with the Audit Report for the quarter and full year ended March 31, 2025, under Regulation 33 of SEBI LODR. The filing was signed by Director Vimal D. Shah (DIN: 01506655). The trading window for dealing in the company's securities has already been closed from April 1, 2025, and will reopen 48 hours after the audited results are declared to the stock exchange.
This is a routine procedural filing ahead of the annual results announcement. Investors should watch May 28, 2025, for the actual Q4 and FY25 numbers, which could drive short-term stock movement. No new financial information is disclosed in this intimation itself.